Rapid and robust evolution of collateral sensitivity in


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
08 2020
Historique:
received: 12 12 2019
accepted: 22 06 2020
entrez: 22 8 2020
pubmed: 22 8 2020
medline: 12 4 2022
Statut: epublish

Résumé

The analysis of trade-offs, as collateral sensitivity, associated with the acquisition of antibiotic resistance, is mainly based on the use of model strains. However, the possibility of exploiting these trade-offs for fighting already resistant isolates has not been addressed in depth, despite the fact that bacterial pathogens are frequently antibiotic-resistant, forming either homogeneous or heterogeneous populations. Using a set of

Identifiants

pubmed: 32821825
doi: 10.1126/sciadv.aba5493
pii: aba5493
pmc: PMC7406369
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ceftazidime 9M416Z9QNR
Tobramycin VZ8RRZ51VK

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eaba5493

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Références

Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29084746
Drugs. 2003;63(22):2501-20
pubmed: 14609360
Mol Biol Evol. 2017 Sep 1;34(9):2229-2244
pubmed: 28541480
Front Genet. 2018 Oct 18;9:451
pubmed: 30405685
mBio. 2018 May 15;9(3):
pubmed: 29764951
Proc Biol Sci. 2016 May 11;283(1830):
pubmed: 27170722
Environ Microbiol. 2016 Oct;18(10):3482-3493
pubmed: 27119970
Gene. 1998 May 28;212(1):77-86
pubmed: 9661666
PLoS Biol. 2017 Aug 8;15(8):e2001586
pubmed: 28792497
Antimicrob Agents Chemother. 2013 Nov;57(11):5406-14
pubmed: 23959314
Nat Commun. 2014 Jul 08;5:4352
pubmed: 25000950
PLoS Genet. 2009 Jul;5(7):e1000578
pubmed: 19629166
Nat Commun. 2019 Jan 18;10(1):334
pubmed: 30659188
Environ Microbiol. 2012 Aug;14(8):2200-11
pubmed: 22672046
PLoS Genet. 2011 Mar;7(3):e1001321
pubmed: 21408208
Mol Biol Evol. 2019 Oct 1;36(10):2238-2251
pubmed: 31228244
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30082283
PLoS One. 2013;8(4):e60225
pubmed: 23573242
Trends Microbiol. 2015 Jul;23(7):401-7
pubmed: 25818802
Antimicrob Agents Chemother. 2016 Jan 04;60(3):1767-78
pubmed: 26729493
Microbiology. 2009 Apr;155(Pt 4):1050-1057
pubmed: 19332807
Science. 2014 Sep 12;345(6202):1299-301
pubmed: 25214620
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14494-9
pubmed: 25246554
Science. 2014 Jun 27;344(6191):1519-1522
pubmed: 24970088
Science. 2016 Jan 1;351(6268):aad3292
pubmed: 26722002
Nat Commun. 2018 Sep 10;9(1):3673
pubmed: 30202004
Sci Transl Med. 2013 Sep 25;5(204):204ra132
pubmed: 24068739
Nat Commun. 2016 Oct 03;7:13002
pubmed: 27694971
Am J Respir Crit Care Med. 2014 Aug 1;190(3):289-97
pubmed: 24937177
Sci Transl Med. 2014 Nov 12;6(262):262ra156
pubmed: 25391482
PLoS Pathog. 2010 Jan 22;6(1):e1000735
pubmed: 20107608
J Bacteriol. 1952 Oct;64(4):489-99
pubmed: 12999676
Antimicrob Agents Chemother. 2010 Oct;54(10):4159-67
pubmed: 20679510
Antimicrob Agents Chemother. 2019 Sep 30;:
pubmed: 31570397
Cell. 2018 Jan 11;172(1-2):121-134.e14
pubmed: 29307490
J Evol Biol. 2009 May;22(5):997-1003
pubmed: 19298493
Mol Biol Evol. 2019 Aug 1;36(8):1601-1611
pubmed: 31058961
J Antimicrob Chemother. 2018 Dec 1;73(12):3322-3331
pubmed: 30189050
PLoS Biol. 2018 Apr 30;16(4):e2004356
pubmed: 29708964
Antimicrob Agents Chemother. 2000 Sep;44(9):2242-6
pubmed: 10952562
Elife. 2019 Oct 29;8:
pubmed: 31658946
Mol Syst Biol. 2013 Oct 29;9:700
pubmed: 24169403

Auteurs

Sara Hernando-Amado (S)

Centro Nacional de Biotecnología, CSIC, 28049 Madrid, Spain.

Fernando Sanz-García (F)

Centro Nacional de Biotecnología, CSIC, 28049 Madrid, Spain.

José Luis Martínez (JL)

Centro Nacional de Biotecnología, CSIC, 28049 Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH